combination

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

indie 28 9 月

6 minutes

HONG KONG, Sep 28, 2022 – […]

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

ruth 6 9 月

3 minutes

TOKYO, Sep 6, 2022 – (JC […]

Eisai Contributes to the Science of Cancer Medicine at ASCO 2022

ruth 27 5 月

3 minutes

TOKYO, May 27, 2022 – (J […]

Hua Medicine Announces 2021 Annual Results

indie 17 3 月

8 minutes

SHANGHAI, CHINA, Mar 17, 2022 […]

LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma

ruth 7 3 月

7 minutes

TOKYO, Mar 7, 2022 – (JC […]

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

ruth 31 1 月

8 minutes

TOKYO, Jan 31, 2022 – (J […]

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

ruth 17 1 月

4 minutes

TOKYO, Jan 17, 2022 – (J […]

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

ruth 1 11 月

5 minutes

TOKYO, Nov 1, 2021 – (JC […]

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

indie 8 9 月

6 minutes

NEW JERSEY, the U.S. and HANGZ […]

Hua Medicine Announces 2020 Interim Results

indie 19 8 月

7 minutes

SHANGHAI, CHINA, Aug 19, 2021 […]

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)

ruth 12 8 月

18 minutes

TOKYO and KENILWORTH, N.J., Au […]

Black Spade Acquisition Co Announces Pricing of $150 Million Initial Public Offering

indie 16 7 月

4 minutes

HONG KONG, Jul 16, 2021 – […]

Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

ruth 20 5 月

3 minutes

TOKYO, May 20, 2021 – (J […]

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

ruth 31 3 月

2 minutes

TOKYO, Mar 31, 2021 – (J […]

Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

ruth 30 3 月

4 minutes

TOKYO, Mar 30, 2021 – (J […]

APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA

indie 4 3 月

3 minutes

FOSTER CITY, Calif. and HANGZH […]

Copyright © 2020 ASEANPR.Com All rights reserved.